Law & Regulation
DEA resists permitting psilocybin for terminal patients under ‘Right to Try’
The agency contends that "Right-to-Try" laws do not supersede the Controlled Substances Act.
The post DEA resists permitting psilocybin for terminal patients…
A long-running showdown between a doctor and the U.S. Drug Enforcement Administration that could affect the legal status of psychedelics is heating up.
The agency last week urged the Ninth Circuit Court of Appeal to block the physician’s efforts to use psilocybin to treat depression in terminally ill cancer patients, Law360 reported. The case centers on the scope and application of federal and state “Right-to-Try” laws, which allows the use of unapproved, investigational drugs for therapeutic purposes.
Dr. Sunil Aggarwal, co-founder of Seattle-based psychedelics research and treatment clinic, Advanced Integrative Medical Science Institute (AIMS), has repeatedly argued that the Right to Try Act grants him the authority to administer psilocybin to his patients.
However, in a new filing, the DEA maintained that the Right to Try Act only amends the Federal Food, Drug, and Cosmetic Act and does not impact the restrictions imposed by the CSA. The agency asserted that doctors who wish to dispense controlled substances must comply with both sets of regulations.
“The CSA and the FDCA (which the Right to Try Act amends) are separate regulatory schemes with separate requirements and restrictions,” the DEA wrote. “Nothing in the Right to Try Act changes that.”
Aggarwal, who has been engaged in litigation over this for a few years now, says that psilocybin has shown promise in treating major depression in clinical trials and should be accessible to terminally ill patients. However, the DEA has repeatedly rejected his proposals, stating in a 2022 denied petition that offering psilocybin to terminally ill patients would not be consistent with public health and safety.
The doctor also claimed that the DEA wants him to register as a researcher to obtain the drug, which goes against the law.
That led him to appeal to the Ninth Circuit on the grounds that the agency’s decisions were arbitrary and contradict public health interests and established legal precedents. In February, he argued that the DEA must explain how their decision aligns with the CSA and the agency’s own precedent, since the DEA has granted waivers for therapeutic use of other drugs, like cannabis for children.
The DEA doubled down on its position, arguing that Aggarwal has not provided adequate evidence to support his claims. The agency also contended that it could not fully evaluate Aggarwal’s proposal because he failed to provide the text or scope of the waiver he was seeking.
Psilocybin is currently classified as a Schedule I drug, meaning it has no accepted medical use. However, the drug has received “breakthrough therapy status” from the FDA twice and is currently in stage III clinical trials.
It remains unclear when the appellate court may issue a ruling on this case.
In a separate case, the Ninth Circuit ordered the DEA to clarify why psilocybin should remain a Schedule I substance after the agency rejected Aggarwal’s petition to move it to Schedule II, which is for drugs with accepted medical use but severe restrictions.
deapsychedelicsappealThe post DEA resists permitting psilocybin for terminal patients under ‘Right to Try’ appeared first on Green Market Report.
laws fda research psychedelics psilocybin-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders
-
Psychedelics1 week ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Law & Regulation1 week ago
Adastra reports record sales in 2023, but remains in the red